Ethris' proprietary platforms for stabilised and low-immunogenic mRNA and customised lipid nanoparticles are at the heart of the project. The vaccine material is produced by industrial partners such as Patheon and Evonik, which enables quality-assured production on an industrial scale. The DZIF contributes its translational expertise in vaccine research and drives preclinical and clinical programmes. Both partners are focussing on a change in strategy. In future, vaccines should not only respond to acute crises, but also offer long-term protection and be effective in the case of difficult-to-treat infections or antibiotic resistance. The collaboration combines academic excellence with industrial implementation power and could pave the way for more robust mRNA concepts.
Press release of the "German Centre for Infection Research e. V." from 09.02.2026